Cargando…

Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records

AIMS: Transthyretin amyloid cardiomyopathy (ATTR‐CM), a progressive and fatal cardiomyopathy, is frequently misdiagnosed or entails diagnostic delays, hindering patients from timely treatment. This study aimed to generate a systematic framework based on data from electronic health records (EHRs) to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moya, Ana, Oeste, Clara L., Beles, Monika, Verstreken, Sofie, Dierckx, Riet, Heggermont, Ward, Bartunek, Jozef, Bogaerts, Eline, Masuy, Imke, Hens, Dries, Bertolone, Dario, Vanderheyden, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682883/ https://www.ncbi.nlm.nih.gov/pubmed/37726928 http://dx.doi.org/10.1002/ehf2.14517

Ejemplares similares

Cardio–renal–metabolic syndrome: clinical features and dapagliflozin eligibility in a real‐world heart failure cohort
por: Beles, Monika, et al.
Publicado: (2023)

Circulating SERPINA3 improves prognostic stratification in patients with a de novo or worsened heart failure
por: Delrue, Leen, et al.
Publicado: (2021)

T Cell and Antibody Response Following Double Dose of BNT162b2 mRNA Vaccine in SARS-CoV-2 Naïve Heart Transplant Recipients
por: Delrue, Leen, et al.
Publicado: (2022)

Utilizing longitudinal data in assessing all‐cause mortality in patients hospitalized with heart failure
por: Herman, Robert, et al.
Publicado: (2022)

Low MicroRNA-126 Levels in Right Ventricular Endomyocardial Biopsies Coincide With Cardiac Allograft Vasculopathy in Heart Transplant Patients
por: Heggermont, Ward A., et al.
Publicado: (2020)

Hemodynamic Response to Acute Volume Load and Endomyocardial NO-synthase Gene Expression in Heart Transplant Recipients
por: Kobediona, Monika, et al.
Publicado: (2022)

Serial Non-Invasive Myocardial Work Measurements for Patient Risk Stratification and Early Detection of Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients: A Single-Centre Observational Study
por: Moya, Ana, et al.
Publicado: (2023)

Vessel Fractional Flow Reserve and Graft Vasculopathy in Heart Transplant Recipients
por: Nagumo, Sakura, et al.
Publicado: (2020)

Validation of Coronary Angiography-Derived Vessel Fractional Flow Reserve in Heart Transplant Patients with Suspected Graft Vasculopathy
por: Mileva, Niya, et al.
Publicado: (2021)

Novel IVC Doraya Catheter Provides Congestion Relief in Patients With Acute Heart Failure
por: Zymliński, Robert, et al.
Publicado: (2022)

Diagnosis of Transthyretin Amyloid Cardiomyopathy
por: Hafeez, Adam S., et al.
Publicado: (2020)

Hereditary transthyretin amyloid cardiomyopathy
por: Zheng, Yiliang, et al.
Publicado: (2023)

Safety, Feasibility of Controllable Decrease of Vena Cava Pressure by Doraya Catheter in Heart Failure
por: Zymliński, Robert, et al.
Publicado: (2023)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Speckle Tracking and Transthyretin Amyloid Cardiomyopathy
por: Rocha, Alexandre Marins, et al.
Publicado: (2017)

Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)

Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function
por: Nakano, Tomoya, et al.
Publicado: (2022)

Aortic thoracic neuromodulation in heart failure with preserved ejection fraction
por: Paolisso, Pasquale, et al.
Publicado: (2022)

Multi-modality imaging in transthyretin amyloid cardiomyopathy
por: Traynor, Bryan Paul, et al.
Publicado: (2019)

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023)

Performance of non‐invasive myocardial work to predict the first hospitalization for de novo heart failure with preserved ejection fraction
por: Paolisso, Pasquale, et al.
Publicado: (2021)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
por: Porcari, Aldostefano, et al.
Publicado: (2020)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
por: Lauppe, Rosa Elisabeth, et al.
Publicado: (2021)

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
por: Lauppe, Rosa, et al.
Publicado: (2022)

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy
por: Nuvolone, Mario, et al.
Publicado: (2022)

Incidence and Predictors of Ventricular Arrhythmias in Transthyretin Amyloid Cardiomyopathy
por: Knoll, Katharina, et al.
Publicado: (2023)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020)

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges
por: Bruno, Marianna, et al.
Publicado: (2020)

A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Singh, Bishnu Mohan, et al.
Publicado: (2021)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges
por: Tschöpe, Carsten, et al.
Publicado: (2022)

Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity
por: Robinson, Emma L., et al.
Publicado: (2023)

Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
por: He, Shan, et al.
Publicado: (2019)

Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
por: Feng, Kent Y., et al.
Publicado: (2019)

Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia
por: Lin, Weiqin, et al.
Publicado: (2022)

Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries
por: Lauppe, Rosa, et al.
Publicado: (2022)

Endothelial Function Is Preserved in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy
por: Hashimoto, Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5skia85ll0gffdtv433o5ctnjc